The latest developments across the GLP-1 landscape, from new drug approvals and clinical research to pricing changes and policy shifts. Stay informed on the updates that affect Ozempic, Wegovy, Mounjaro, and the wider category.
News & Updates
Aspen Pharmacare has received Canadian approval to sell a generic version of semaglutide, the active ingredient in Ozempic, following Novo Nordisk's patent expiry in Canada. This marks a significant shift in the GLP-1 landscape that could eventually affect pricing and access across North America. Here is what patients and those considering GLP-1 therapy need to know.
GLP-1 retreats are emerging as a premium option for people on semaglutide or tirzepatide who want structured lifestyle coaching alongside their medication. But do they deliver results that justify the price tag? Here's what you need to know before booking one.
Novo Nordisk has launched a more affordable version of Ozempic in South Africa, raising questions about global GLP-1 pricing and what it could mean for patients in other markets. Here's a breakdown of the move and its broader implications for drug access and cost.
Major fast food chains are quietly restructuring their menus in response to the growing number of Americans on GLP-1 medications. For patients on semaglutide or tirzepatide, this cultural shift reflects a broader change in how the food industry views hunger, portion size, and appetite. Here's what it means for you.
Novo Nordisk has received its first European approval for an oral version of Wegovy, bringing a pill-based semaglutide option closer to reality for weight loss patients. This is a significant step beyond the current injectable format. Here's what it means for people considering or currently using GLP-1 medications.
UVM Health Network is eliminating GLP-1 weight-loss drug coverage for its employees, leaving many workers scrambling for alternatives. This move reflects a broader national trend of employers pulling back on obesity medication benefits due to high costs. If you're affected, here's what you need to know and what steps to take next.
Novo Nordisk is preparing to launch a lower-cost version of Ozempic in South Africa, signaling a potential shift in how the company prices semaglutide across different markets. For patients in the U.S. and elsewhere who struggle with GLP-1 medication costs, this move raises important questions about global pricing fairness and what alternatives exist today.
Compounding pharmacies continue to supply a significant portion of GLP-1 medications in the U.S., even as brand-name drugs like Ozempic and Wegovy return to shelves. This article breaks down what that market reality means for patients weighing cost, access, and safety when choosing between compounded and brand-name options.
.avif)
